Strategies for half-life extension are often required in the design of new biopharmaceuticals. This Viewpoint focuses on chemical moieties that convey protraction by albumin binding or by self-assembly to form larger structures, with GLP-1 and insulin as examples.
Noncovalent binding of biopharmaceuticals to human serum albumin protects against enzymatic degradation and renal clearance. Herein, we investigated the effect of mono- or divalent small-molecule albumin binders for half-life extension of peptides. For proof-of-principle, the clinically relevant glucagon-like peptide 1 (GLP-1) was functionalized with diflunisal, indomethacin, or both. In vitro, all GLP-1 analogues had subnanomolar GLP-1 receptor potency. Surface plasmon resonance revealed that both small molecules were able to confer albumin affinity to GLP-1 and indicated that affinity is increased for divalent analogues. In lean mice, the divalent GLP-1 analogues were superior to monovalent analogues with respect to control of glucose homeostasis and suppression of food intake. Importantly, divalent GLP-1 analogues showed efficacy comparable to liraglutide, an antidiabetic GLP-1 analogue that carries a long-chain fatty acid. Finally, pharmacokinetic investigations of a divalent GLP-1 analogue demonstrated a promising gain in circulatory half-life and absorption time compared to its monovalent equivalent.
Novel principles for optimizing the properties of peptide-based drugs are needed in order to leverage their full pharmacological potential. We present the design, synthesis, and evaluation of a library of neoglycolipidated glucagon-like peptide 1 (GLP-1) analogues, which are valuable drug candidates for treatment of type 2 diabetes and obesity. Neoglycolipidation of GLP-1 balanced the lipophilicity, directed formation of soluble oligomers, and mediated albumin binding. Moreover, neoglycolipidation did not compromise bioactivity, as in vitro potency of neoglycolipidated GLP-1 analogues was maintained or even improved compared to native GLP-1. This translated into pronounced in vivo efficacy in terms of both decreased acute food intake and improved glucose homeostasis in mice. Thus, we propose neoglycolipidation as a novel, general method for modulating the properties of therapeutic peptides.
Peptide YY3–36 (PYY3–36) is
an endogenous ligand of the neuropeptide Y2 receptor (Y2R), on which it acts to reduce food intake. Chemically modified
PYY3–36 analogues with extended half-lives are potential
therapeutics for the treatment of obesity. Here we show that the common
half-life extending strategies PEGylation and lipidation not only
control PYY3–36’s pharmacokinetics but also
affect central aspects of its pharmacodynamics. PEGylation of PYY3–36 inhibited endocytosis by increasing receptor dissociation
rates (k
off), which reduced arrestin-3
(Arr3) activity. This is the first link between Arr3 recruitment and
Y2R residence time. C16-lipidation of PYY3–36 had a negligible impact on Y2R signaling, binding, and
endocytosis. In contrast, C18acid-lipidation minimized endocytosis,
which indicated a decreased internalization through non-arrestin-related
mechanisms. We propose a temporal model that connects the properties
and position of the half-life extender with receptor Gi versus Arr3 signaling bias. We believe that this will be important
for future design of peptide therapeutics.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.